Enhanced therapeutic effects against murine colon carcinoma induced by a Colon 26/Ag85A-CD226 tumor cell vaccine

Li,Yan; Yang,Fangli; Sang,Lixuan; Zhu,Junfeng; Han,Xue; Shan,Fengping; Li,Shengjun; Zhai,Jingbo; Wang,Danan; Lu,Changlong; Sun,Xun

doi:10.3892/or.2015.4137

Enhanced therapeutic effects against murine colon carcinoma induced by a Colon 26/Ag85A-CD226 tumor cell vaccine

Authors:
- Yan Li
- Fangli Yang
- Lixuan Sang
- Junfeng Zhu
- Xue Han
- Fengping Shan
- Shengjun Li
- Jingbo Zhai
- Danan Wang
- Changlong Lu
- Xun Sun
View Affiliations

Affiliations: Department of Immunology, School of Basic Medical Science, China Medical University, Heping, Shenyang, Liaoning 110001, P.R. China
Published online on: July 20, 2015 https://doi.org/10.3892/or.2015.4137
Pages: 1795-1804

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Genetically modified tumor cells represent one of the most effective cancer vaccine strategies. In the present study, we describe our approach for inducing an immune response against a colon carcinoma in BALB/c mice, using a Colon 26 tumor cell line expressing Ag85A and CD226. We investigated whether CD226 plays a promotive role for Ag85A against Colon 26 colon carcinoma. The therapeutic efficacy was investigated. The cytotoxic T lymphocyte (CTL) and natural killer (NK) cell cytotoxicity were assessed. Dynamic changes in interferon (IFN)-γ levels in the spleen and the number of IFN-γ-producing CD4+ or CD8+ T cells in the spleen or mesenteric lymph nodes were detected by enzyme-linked immunoabsorbent assay or flow cytometry. Extended survival times, delayed appearances of tumors, and reduced tumor volumes were achieved by preventive vaccination with the Colon 26/Ag85A-CD226 tumor cell vaccine. NK cell or CTL cytotoxicity in the spleens of mice immunized with the Colon 26/Ag85A-CD226 tumor cell vaccine was significantly higher than that in the other treatment groups. The numbers of CD4+ IFN-γ+ and CD8+ IFN-γ+ T cells were both significantly increased in mice immunized with the Colon 26/Ag85A-CD226 tumor cell vaccine in both the spleen and mesenteric lymph nodes. Our results indicated that the tumor vaccine expressing Ag85A and CD226 induced more intensive antitumor immunity than tumor vaccine expressing Ag85A or CD226 only. Moreover, the results suggest that Ag85A and CD226 play a synergistic antitumor effect and CD226 could be used as a genetic adjuvant to enhance the effects of Ag85A vaccine against murine colon carcinoma.

View Figures

View References

1	Esteban-Jurado C, Garre P, Vila M, Lozano JJ, Pristoupilova A, Beltrán S, Abulí A, Muñoz J, Balaguer F, Ocaña T, et al: New genes emerging for colorectal cancer predisposition. World J Gastroenterol. 20:1961–1971. 2014. View Article : Google Scholar : PubMed/NCBI
2	Li HZ, Mao WM, Wang XH, Yu CD and Du LB: Incidence and mortality of cancer in Zhejiang province in 2009. Zhonghua Yu Fang Yi Xue Za Zhi. 47:592–596. 2013.In Chinese. PubMed/NCBI
3	Yi N, Xiao MB, Ni WK, Jiang F, Lu CH and Ni RZ: High expression of peroxiredoxin 4 affects the survival time of colorectal cancer patients, but is not an independent unfavorable prognostic factor. Mol Clin Oncol. 2:767–772. 2014.PubMed/NCBI
4	Yang Z, Bai Y, Huo L, Chen H, Huang J, Li J, Fan X, Yang Z, Wang L and Wang J: Expression of A disintegrin and metalloprotease 8 is associated with cell growth and poor survival in colorectal cancer. BMC Cancer. 14:5682014. View Article : Google Scholar : PubMed/NCBI
5	Kim J, Huynh R, Abraham I, Kim E and Kumar RR: Number of lymph nodes examined and its impact on colorectal cancer staging. Am Surg. 72:902–905. 2006.PubMed/NCBI
6	Jemal A, Center MM, DeSantis C and Ward EM: Global patterns of cancer incidence and mortality rates and trends. Cancer Epidemiol Biomarkers Prev. 19:1893–1907. 2010. View Article : Google Scholar : PubMed/NCBI
7	Belisle JT, Vissa VD, Sievert T, Takayama K, Brennan PJ and Besra GS: Role of the major antigen of Mycobacterium tuberculosis in cell wall biogenesis. Science. 276:1420–1422. 1997. View Article : Google Scholar : PubMed/NCBI
8	Huygen K, Content J, Denis O, Montgomery DL, Yawman AM, Deck RR, DeWitt CM, Orme IM, Baldwin S, D'Souza C, et al: Immunogenicity and protective efficacy of a tuberculosis DNA vaccine. Nat Med. 2:893–898. 1996. View Article : Google Scholar : PubMed/NCBI
9	Borremans M, de Wit L, Volckaert G, Ooms J, de Bruyn J, Huygen K, van Vooren JP, Stelandre M, Verhofstadt R and Content J: Cloning, sequence determination, and expression of a 32-kilodalton-protein gene of Mycobacterium tuberculosis. Infect Immun. 57:3123–3130. 1989.PubMed/NCBI
10	Montgomery DL, Huygen K, Yawman AM, Deck RR, Dewitt CM, Content J, Liu MA and Ulmer JB: Induction of humoral and cellular immune responses by vaccination with M. tuberculosis antigen 85 DNA. Cell Mol Biol (Noisy-le-grand). 43:285–292. 1997.
11	Dou J, Tang Q, Yu F, Yang H, Zhao F, Xu W, Wang J, Hu W, Hu K and Liou C: Investigation of immunogenic effect of the BCG priming and Ag85A-GM-CSF boosting in Balb/c mice model. Immunobiology. 215:133–142. 2010. View Article : Google Scholar
12	Dou J, Wang Y, Yu F, Yang H, Wang J, He X, Xu W, Chen J and Hu K: Protection against Mycobacterium tuberculosis challenge in mice by DNA vaccine Ag85A-ESAT-6-IL-21 priming and BCG boosting. Int J Immunogenet. 39:183–190. 2012. View Article : Google Scholar
13	Wang D, Xu J, Feng Y, Liu Y, Mchenga SS, Shan F, Sasaki J and Lu C: Liposomal oral DNA vaccine (mycobacterium DNA) elicits immune response. Vaccine. 28:3134–3142. 2010. View Article : Google Scholar : PubMed/NCBI
14	Liu CS, Wu Y, Dou J, Wen P, Zhao FS, Tang Q, Li JL and Wang YQ: Study of anti-melanoma effect in mice injected with melanoma cells transfected with the recombinant expressing Ag85A and GM-CSF. J Southeast Univ. 29:57–61. 2010.
15	Zhang P, Wang J, Wang D, Wang H, Shan F, Chen L, Hou Y, Wang E and Lu CL: Dendritic cell vaccine modified by Ag85A gene enhances anti-tumor immunity against bladder cancer. Int Immunopharmacol. 14:252–260. 2012. View Article : Google Scholar : PubMed/NCBI
16	Shibuya A, Campbell D, Hannum C, Yssel H, Franz-Bacon K, McClanahan T, Kitamura T, Nicholl J, Sutherland GR, Lanier LL, et al: DNAM-1, a novel adhesion molecule involved in the cytolytic function of T lymphocytes. Immunity. 4:573–581. 1996. View Article : Google Scholar : PubMed/NCBI
17	Shirakawa J, Shibuya K and Shibuya A: Requirement of the serine at residue 329 for lipid raft recruitment of DNAM-1 (CD226). Int Immunol. 17:217–223. 2005. View Article : Google Scholar : PubMed/NCBI
18	Seth S, Georgoudaki AM, Chambers BJ, Qiu Q, Kremmer E, Maier MK, Czeloth N, Ravens I, Foerster R and Bernhardt G: Heterogeneous expression of the adhesion receptor CD226 on murine NK and T cells and its function in NK-mediated killing of immature dendritic cells. J Leukoc Biol. 86:91–101. 2009. View Article : Google Scholar : PubMed/NCBI
19	Li Y, Yang F, Zhu J, Sang L, Han X, Wang D, Shan F, Li S, Sun X and Lu C: CD226 as a genetic adjuvant to enhance immune efficacy induced by Ag85A DNA vaccination. Int Immunopharmacol. 25:10–18. 2015. View Article : Google Scholar : PubMed/NCBI
20	Tuominen VJ, Ruotoistenmäki S, Viitanen A, Jumppanen M and Isola J: ImmunoRatio: A publicly available web application for quantitative image analysis of estrogen receptor (ER), progesterone receptor (PR), and Ki-67. Breast Cancer Res. 12:R562010. View Article : Google Scholar : PubMed/NCBI
21	Marcusson-Ståhl M and Cederbrant K: A flow-cytometric NK-cytotoxicity assay adapted for use in rat repeated dose toxicity studies. Toxicology. 193:269–279. 2003. View Article : Google Scholar : PubMed/NCBI
22	Zhao F, Dou J, Wang J, Chu L, Tang Q, Wang Y, Li Y, Cao M, Hu W and Hu K: Investigation on the anti-tumor efficacy by expression of GPI-anchored mIL-21 on the surface of B16F10 cells in C57BL/6 mice. Immunobiology. 215:89–100. 2010. View Article : Google Scholar
23	Clive KS, Tyler JA, Clifton GT, Holmes JP, Mittendorf EA, Ponniah S and Peoples GE: Use of GM-CSF as an adjuvant with cancer vaccines: Beneficial or detrimental? Expert Rev Vaccines. 9:519–525. 2010. View Article : Google Scholar : PubMed/NCBI
24	Miguel A, Herrero MJ, Sendra L, Botella R, Algás R, Sánchez M and Aliño SF: Comparative antitumor effect among GM-CSF, IL-12 and GM-CSF+IL-12 genetically modified tumor cell vaccines. Cancer Gene Ther. 20:576–581. 2013. View Article : Google Scholar : PubMed/NCBI
25	Olivares J, Kumar P, Yu Y, Maples PB, Senzer N, Bedell C, Barve M, Tong A, Pappen BO, Kuhn J, et al: Phase I trial of TGF-beta 2 antisense GM-CSF gene-modified autologous tumor cell (TAG) vaccine. Clin Cancer Res. 17:183–192. 2011. View Article : Google Scholar : PubMed/NCBI
26	Agarwalla P, Barnard Z, Fecci P, Dranoff G and Curry WT Jr: Sequential immunotherapy by vaccination with GM-CSF-expressing glioma cells and CTLA-4 blockade effectively treats established murine intracranial tumors. J Immunother. 35:385–389. 2012. View Article : Google Scholar : PubMed/NCBI
27	Seth S, Qiu Q, Danisch S, Maier MK, Braun A, Ravens I, Czeloth N, Hyde R, Dittrich-Breiholz O, Förster R, et al: Intranodal interaction with dendritic cells dynamically regulates surface expression of the co-stimulatory receptor CD226 protein on murine T cells. J Biol Chem. 286:39153–39163. 2011. View Article : Google Scholar : PubMed/NCBI
28	Burgdorf SK, Claesson MH, Nielsen HJ and Rosenberg J: Changes in cytokine and biomarker blood levels in patients with colorectal cancer during dendritic cell-based vaccination. Acta Oncol. 48:1157–1164. 2009. View Article : Google Scholar : PubMed/NCBI
29	Nishimura T, Nakui M, Sato M, Iwakabe K, Kitamura H, Sekimoto M, Ohta A, Koda T and Nishimura S: The critical role of Th1-dominant immunity in tumor immunology. Cancer Chemother Pharmacol. 46(Suppl): S52–S61. 2000. View Article : Google Scholar : PubMed/NCBI